Dublin, Aug. 01, 2023 (GLOBE NEWSWIRE) -- The "Scleroderma - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering.
This "Scleroderma- Pipeline Insight, 2023" report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Scleroderma pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Scleroderma pipeline landscape is provided which includes the disease overview and Scleroderma treatment guidelines.
The assessment part of the report embraces, in depth Scleroderma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Scleroderma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Scleroderma R&D. The therapies under development are focused on novel approaches to treat/improve Scleroderma.
Scleroderma Emerging Drugs Chapters
This segment of the Scleroderma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Scleroderma Emerging Drugs
FT011: Certa Therapeutics
FT011 is a novel drug that inhibits this GPCR, offering the potential to treat chronic fibrosis in multiple organs. Breakthrough research conducted by Certa Therapeutics has identified a novel biologic target in the fibrosis mechanism as a defined G protein-coupled receptor (GPCR).
This GPCR is silent in healthy tissue but activates following injury or disease. Evidence demonstrates the role this GPCR has in multiple downstream pathways causing inflammation and fibrosis. Currently, the drug is in the Phase II stage of its development for the treatment of scleroderma.
EHP 101: Emerald Health Pharmaceuticals
EHP-101 is an oral formulation of a new chemical entity derived from synthetic cannabidiol, also known as CBD, one of the most abundant molecules found in the cannabis plant. The fully synthetic novel molecule formulated in EHP-101 has been rationally designed to enhance the therapeutic benefits of CBD by being a dual peroxisome proliferator-activated receptor gamma (PPARg) and cannabinoid type 2 receptor (CB2) agonist that also activates the hypoxia inducible factor (HIF) pathway. The drug is currently in the Phase II stage of its development for the treatment of scleroderma.
ACE-1334: Acceleron Pharma
ACE-1334 is an Acceleron-discovered, TGF-beta superfamily-based ligand trap designed to bind and inhibit TGF-beta 1 and 3 ligands but not TGF-beta 2. TGF-beta 1 and 3 are believed to be key signaling factors in the pathogenesis of fibrotic disease. ACE-1334 has shown robust anti-fibrotic activity in multiple preclinical models of fibrosis. ACE-1334 completed an ascending-dose Phase I clinical trial in healthy volunteers.
The FDA has granted Fast Track designation to ACE-1334 in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) as well as Orphan Drug designation for the treatment of systemic sclerosis. In November 2021, Merck announced the successful completion of the acquisition of Acceleron Pharma. Currently, the drug is in the Phase I stage of its development for the treatment of systemic scleroderma.
Scleroderma: Therapeutic Assessment
This segment of the report provides insights about the different Scleroderma drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Scleroderma
There are approx. 45+ key companies which are developing the therapies for Scleroderma. The companies which have their Scleroderma drug candidates in the most advanced stage, i.e. phase III include, Certa Therapeutics.
Scleroderma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Scleroderma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Scleroderma drugs.
Key Questions Answered
- How many companies are developing Scleroderma drugs?
- How many Scleroderma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Scleroderma?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Scleroderma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Scleroderma and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Biocad
- Certa Therapeutics
- Emerald Health Pharmaceuticals
- Acceleron Pharma
- Kyowa Kirin
- Bayer
- Boehringer Ingelheim
- Maruho Co., Ltd.
- Mitsubishi Tanabe Pharma
- Prometheus Biosciences
Key Products
- FT011
- EHP 101
- ACE-1334
- Riociguat
- Divozilimab
- BI 685509
- KHK4827
- Nemolizumab
- MT-7117
- PRA023
Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Scleroderma Report Insights
- Scleroderma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Scleroderma Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/n40mf5
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
